Antagonists of protein-protein interactions

Chemistry and Biology

Volumn 7, Issue 4, 2000, Pages

  Cochran, Andrea G ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH THROUGHPUT SCREENING; PHAGE DISPLAY; PROTEIN PROTEIN INTERACTION; THERAPY;

EID: 0034177264     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(00)00106-X     Document Type: Review

References (75)

1. Marcotte E.M., Pellegrini M., Ng H-L., Rice D.W., Yeates T.O., Eisenberg D. Detecting protein function and protein-protein interactions from genome sequences. Science. 285:1999;751-753.
2. Rohrer S.P.et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 282:1998;737-740.
3. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 23:1997;3-25.
4. Nguyen J.T., Turck C.W., Cohen F.E., Zuckermann R.N., Lim W.A.et al. Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors. Science. 282:1998;2088-2092.
5. Wells J.A. Binding in the growth hormone receptor complex. Proc. Natl Acad. Sci. USA. 93:1996;1-6.
6. Wells J.A., de Vos A.M. Hematopoietic receptor complexes. Annu. Rev. Biochem. 65:1996;609-634.
7. Bemis G.W., Murcko M.A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39:1996;2887-2893.
8. Ajay X., Walters W.P., Murcko M.A. Can we learn to distinguish between `drug-like' and `nondrug-like' molecules? J. Med. Chem. 41:1998;3314-3324.
9. Bemis G.W., Murcko M.A. Properties of known drugs. 2. Side chains. J. Med. Chem. 42:1999;5095-5099.
10. Teague S.J., Davis A.M., Leeson P.D., Oprea T. The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. Engl. 38:1999;3743-3748.
11. Buzko O.V., Shokat K.M. Blocking HIV entry. Nat. Struct. Biol. 6:1999;906-908.
12. Chardin P., McCormick F. Brefeldin A: the advantage of being uncompetitive. Cell. 97:1999;153-155.
13. Ferrell J.E. Jr., Machleder E.M. The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes. Science. 280:1998;895-898.
14. Bhalla U.S., Iyengar R. Emergent properties of networks of biological signaling pathways. Science. 283:1999;381-387.
15. Whitty A., Borysenko C.W. Small-molecule cytokine mimetics. Chem. Biol. 6:1999;R107-R118.
16. Jones S., Thornton J.M. Principles of protein-protein interactions. Proc. Natl Acad. Sci. USA. 93:1996;13-20.
17. Stites W.E. Protein-protein interactions: interface structure, binding thermodynamics and mutational analysis. Chem. Rev. 97:1997;1233-1250.
18. Lo Conte L., Chothia C., Janin J. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285:1999;2177-2198.
19. Clackson T., Wells J.A. A hot spot of binding energy in a hormone-receptor interface. Science. 267:1995;383-386.
20. Liang J., Edelsbrunner H., Woodward C. Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design. Protein Sci. 7:1998;1884-1897.
21. Mattos C., Ringe D. Locating and characterizing binding sites on proteins. Nat. Biotechnol. 14:1996;595-599.
22. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science. 274:1996;1531-1534.
23. Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins. Science. 278:1997;497-499.
24. Hajduk P.J., Olejniczak E.T., Fesik S.W. One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc. 119:1997;12257-12261.
25. Fejzo J.et al. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem. Biol. 6:1999;755-769.
26. Cunningham B.C., Wells J.A. Minimized proteins. Curr. Opin. Struct. Biol. 7:1997;457-462.
27. Braisted A.C., Wells J.A. Minimizing a binding domain from Protein A. Proc. Natl Acad. Sci. USA. 93:1996;5688-5692.
28. Starovasnik M.A., Braisted A.C., Wells J.A. Structural mimicry of a native protein by a minimized binding domain. Proc. Natl Acad. Sci. USA. 94:1997;10080-10085.
29. Vita C.et al. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc. Natl Acad. Sci. USA. 96:1999;13091-13096.
30. Domingues H., Cregut D., Sebald W., Oschkiat H., Serrano L. Rational design of a GCN4-derived mimetic of interleukin-4. Nat. Struct. Biol. 6:1999;652-656.
31. Chen S.et al. Design and synthesis of a CD4 β-turn mimetic that inhibits human immunodeficiency virus envelope glycoprotein gp120 binding and infection of human lymphocytes. Proc. Natl Acad. Sci. USA. 89:1992;5872-5876.
32. Ramurthy S., Lee M.S., Nakanishi H., Shen R., Kahn M. Peptidomimetic antagonists designed to inhibit the binding of CD4 to HIV gp120. Bioorg. Med. Chem. 2:1994;1007-1013.
33. McDowell R.S.et al. From peptide to non-peptide. 1. The elucidation of a bioactive conformation of the arginine-glycine-aspartic acid recognition sequence. J. Am. Chem. Soc. 116:1994;5069-5076.
34. McDowell R.S.et al. From peptide to non-peptide. 2. The de novo design of potent non-peptidal inhibitors of platelet aggregation based on a benzodiazepinedione scaffold. J. Am. Chem. Soc. 116:1994;5077-5083.
35. Quan C.et al. Transfer of a protein binding epitope to a minimal designed peptide. Biopolymers. 47:1998;265-275.
36. Zutshi R., Brickner M., Chmielewski J. Inhibiting the assembly of protein-protein interfaces. Curr. Opin. Chem. Biol. 1998:1998;62-66.
37. Dutia B.M., Frame M.C., Subak-Sharpe J.H., Clark W.N., Marsden H.S. Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides. Nature. 321:1986;439-441.
38. Cohen E.A., Gaudreau P., Brazeau P., Langelier Y. Specific inhibition of herpesvirus ribonucleotide reductase by a nonapeptide derived from the carboxy terminus of subunit 2. Nature. 321:1986;441-443.
39. Uhlin U., Eklund H. Structure of ribonucleotide reductase protein R1. Nature. 370:1994;533-539.
40. Liuzzi M.et al. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature. 372:1994;695-698.
41. Wlodawer A.et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science. 245:1989;616-621.
42. Weber I.T. Comparison of crystal structures and intersubunit interactions of human immunodeficiency and rous sarcoma virus proteases. J. Biol. Chem. 265:1990;10492-10496.
43. Zhang Z-Y., Poorman R.A., Maggiora L.L., Heinrickson R.L., Kézdy F.J. Dissociative inhibition of dimeric enzymes. J. Biol. Chem. 266:1991;15591-15594.
44. Fan X., Flentke G.R., Rich D.H. Inhibition of HIV-1 protease by a subunit of didemnaketal A. J. Am. Chem. Soc. 120:1998;8893-8894.
45. Cwirla S.E., Peters E.A., Barrett R.W., Dower W.J. Peptides on phage: a vast library of peptides for identifying ligands. Proc. Natl Acad. Sci. USA. 87:1990;6378-6382.
46. Scott J.K., Smith G.P. Searching for peptide ligands with an epitope library. Science. 249:1990;386-390.
47. Devlin J.J., Panganiban L.C., Devlin P.E. Random peptide libraries: a source of specific protein binding molecules. Science. 249:1990;404-406.
48. Dower W.J. Targeting growth factor and cytokine receptors with recombinant peptide libraries. Curr. Opin. Chem. Biol. 2:1998;328-334.
49. Sidhu S.S., Lowman H.B., Cunningham B.C., Wells J.A. Phage display for selection of novel binding peptides. Methods Enzymol. 2000;. in press.
50. Kay B.K., Kurakin A.V., Hyde-DeRuyscher R. From peptides to drugs via phage display. Drug Discov. Today. 3:1998;370-378.
51. Wrighton N.C.et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 273:1996;458-463.
52. Livnah O.et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å Science. 273:1996;464-471.
53. Livnah O.et al. An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat. Struct. Biol. 5:1998;993-1004.
54. Yanofsky S.D.et al. High-affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc. Natl Acad. Sci. USA. 93:1996;7381-7386.
55. Lowman H.B.et al. Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1:IGF-binding protein interactions. Biochemistry. 37:1998;8870-8878.
56. Fairbrother W.J.et al. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry. 37:1998;17754-17764.
57. Wiesmann C.et al. Crystal structure of the complex between VEGF and a receptor-blocking peptide. Biochemistry. 37:1998;17765-17772.
58. DeLano W.L., Ultsch M.H., de Vos A.M., Wells J.A. Convergent solutions to binding at a protein-protein interface. Science. 287:2000;1279-1283.
59. Ferrer M., Harrison S.C. Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J. Virol. 73:1999;5795-5802.
60. Tilley J.W.et al. Identification of a small molecule inhibitor of the IL-2/IL-2Rα receptor interaction which binds to IL-2. J. Am. Chem. Soc. 119:1997;7589-7590.
61. Tian S-S.et al. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor. Science. 281:1998;257-259.
62. Qureshi S.A.et al. Mimicry of erythropoietin by a non-peptide molecule. Proc. Natl Acad. Sci. USA. 96:1999;12156-12161.
63. Zhang B.et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science. 284:1999;974-977.
64. Sodroski J.G. HIV-1 entry inhibitors in the side pocket. Cell. 99:1999;243-246.
65. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glyoprotein. Cell. 89:1997;263-273.
66. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 387:1997;426-430.
67. Tan K., Liu J-H., Wang J-H., Shen S., Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl Acad. Sci. USA. 94:1997;12303-12308.
68. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., Matthews T.J. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl Acad. Sci. USA. 91:1994;9770-9774.
69. Judice J.K.et al. Inhibition of HIV type 1 infectivity by constrained α-helical peptides: implications for the viral fusion mechanism. Proc. Natl Acad. Sci. USA. 94:1997;13426-13430.
70. Chan D.C., Chutkowski C.T., Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl Acad. Sci. USA. 95:1998;15613-15617.
71. Ferrer M.et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nature Struct. Biol. 6:1999;953-960.
72. Eckert D.M.et al. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell. 99:1999;103-115.
73. Uetz P.et al. A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature. 403:2000;623-627.
74. Ito T.et al. Toward a protein-protein interaction map of the budding yeast: a comprehensive system to examine two-hybrid interactions in all possible combinations between the yeast proteins. Proc. Natl Acad. Sci. 97:2000;1143-1147.
75. de Vos A.M., Ultsch M., Kossiakoff A.A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 255:1992;306-312.